ClinicalTrials.Veeva

Menu

Intravenous Paracetamol Versus Magnesium Sulfate for Control of Shivering Following Spinal Anesthesia in Cesarean Section

A

Assiut University

Status and phase

Not yet enrolling
Phase 4

Conditions

Post-Spinal Shivering
Shivering

Treatments

Drug: Magnesium Sulfate
Drug: Paracetamol

Study type

Interventional

Funder types

Other

Identifiers

NCT07855588
Paracetamol vs MgSO4 for CS

Details and patient eligibility

About

Spinal anesthesia is widely used for cesarean deliveries, but shivering is a frequent complication that occurs in 40% to 60% of patients. Post-spinal shivering can cause maternal discomfort, increase oxygen consumption and metabolic demands, and interfere with clinical monitoring. Both paracetamol and magnesium sulfate have thermoregulatory properties that may prevent or reduce shivering.

The purpose of this clinical trial is to compare the efficacy and safety of intravenous paracetamol versus intravenous magnesium sulfate in preventing and reducing shivering following spinal anesthesia in women undergoing elective cesarean section.

A total of 90 pregnant women scheduled for elective cesarean delivery will be randomly assigned to one of two groups:

  • Group P (Paracetamol Group): Participants receive intravenous paracetamol (15 mg/kg) infused over 15 minutes immediately following the subarachnoid block.
  • Group M (Magnesium Sulfate Group): Participants receive intravenous magnesium sulfate (30 mg/kg) administered immediately following the subarachnoid block.

The primary outcome evaluated is the severity of post-spinal shivering assessed by shivering scores. Secondary outcomes include hemodynamic parameters (heart rate, blood pressure, oxygen saturation), postoperative pain, complications such as nausea and vomiting, and maternal satisfaction.

Enrollment

90 estimated patients

Sex

Female

Ages

20 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • American Society of Anesthesiologists (ASA) physical status class I or II
  • Pregnant women aged 20 to 40 years
  • Term gestation (>= 37 weeks) with an uncomplicated pregnancy
  • Scheduled for elective cesarean delivery under planned spinal anesthesia
  • Patient agreement and signed written informed consent

Exclusion criteria

  • Patient refusal
  • Morbid obesity (BMI > 35 kg/m²)
  • Contraindications to spinal anesthesia
  • Significant organ dysfunction (e.g., cardiac, respiratory, renal, or hepatic disorders)
  • Known hypersensitivity or allergy to paracetamol or magnesium sulfate
  • Cardiovascular or neuromuscular disorders in which magnesium administration is contraindicated
  • Emergency cesarean section

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

90 participants in 2 patient groups

Group P: Paracetamol Group
Active Comparator group
Description:
Participants receive intravenous paracetamol at a dose of 15 mg/kg infused over 15 minutes immediately after the completion of the subarachnoid block.
Treatment:
Drug: Paracetamol
Group M: Magnesium Sulfate Group
Active Comparator group
Description:
Participants receive intravenous magnesium sulfate at a dose of 30 mg/kg administered immediately after the completion of the subarachnoid block.
Treatment:
Drug: Magnesium Sulfate

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems